{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:14Z","timestamp":1789122734832,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41409-026-02955-5","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:24:34Z","timestamp":1782908674000},"page":"1204-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1717-0428","authenticated-orcid":false,"given":"Ivan J.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace T.","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-4816","authenticated-orcid":false,"given":"Qian Vicky","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Basom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-5304","authenticated-orcid":false,"given":"Yang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2955_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"2955_CR2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022;139:2889\u2013903.","journal-title":"Blood"},{"key":"2955_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"2955_CR4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"2955_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40487-021-00143-7","volume":"9","author":"D Karam","year":"2021","unstructured":"Karam D, Kumar S. Post-Transplant Maintenance Treatment Options in Multiple Myeloma. Oncol Ther. 2021;9:69\u201388.","journal-title":"Oncol Ther"},{"key":"2955_CR6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"2955_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0298-1","volume":"10","author":"S Zhang","year":"2020","unstructured":"Zhang S, Kulkarni AA, Xu B, Chu H, Kourelis T, Go RS, et al. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 2020;10:33.","journal-title":"Blood Cancer J"},{"key":"2955_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020;38:1928\u201337.","journal-title":"J Clin Oncol"},{"key":"2955_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24:64\u201376.","journal-title":"Lancet Oncol"},{"key":"2955_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139\u201350.","journal-title":"Lancet Oncol"},{"key":"2955_CR11","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1200\/JCO.2025.43.16_suppl.7535","volume":"43","author":"AJ Jakubowiak","year":"2025","unstructured":"Jakubowiak AJ, Wrobel T, Jamroziak K, Kubicki T, Robak P, Czyz J, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2025;43:7535.","journal-title":"J Clin Oncol"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"2955_CR13","doi-asserted-by":"crossref","unstructured":"Partanen A., Waage A., Peceliunas V., Schjesvold F., Anttila P., Saily M., et al. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers (Basel);16. 2024.","DOI":"10.3390\/cancers16051024"},{"key":"2955_CR14","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cncr.34778","volume":"129","author":"N Bumma","year":"2023","unstructured":"Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, et al. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023;129:2179\u201391.","journal-title":"Cancer"},{"key":"2955_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"2955_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1198\/016214504000000647","volume":"99","author":"BB Hansen","year":"2004","unstructured":"Hansen BB. Full Matching in an Observational Study of Coaching for the SAT. J Am Stat Assoc. 2004;99:609\u201318.","journal-title":"J Am Stat Assoc"},{"key":"2955_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.2517-6161.1991.tb01848.x","volume":"53","author":"PR Rosenbaum","year":"2018","unstructured":"Rosenbaum PR. A Characterization of Optimal Designs for Observational Studies. J R Stat Soc Ser B. 2018;53:597\u2013610.","journal-title":"J R Stat Soc Ser B"},{"key":"2955_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1037\/0012-1649.44.2.395","volume":"44","author":"EA Stuart","year":"2008","unstructured":"Stuart EA, Green KM. Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes. Dev Psychol. 2008;44:395\u2013406.","journal-title":"Dev Psychol"},{"key":"2955_CR19","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1080\/02664763.2018.1558187","volume":"46","author":"AR Smith","year":"2019","unstructured":"Smith AR, Goodrich NP, Beil CA, Liu Q, Merion RM, Gillespie BW, et al. Graphical representation of survival curves in the presence of time-dependent categorical covariates with application to liver transplantation. J Appl Stat. 2019;46:1702\u201313.","journal-title":"J Appl Stat"},{"key":"2955_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-25-00225","volume":"10","author":"Y Li","year":"2026","unstructured":"Li Y, Qiao Y, Gao F, Gauthier J, Zhang Q, Voutsinas J, et al. Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration. JCO Clin Cancer Inform. 2026;10:e2500225.","journal-title":"JCO Clin Cancer Inform"},{"key":"2955_CR21","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289\u201394.","journal-title":"Blood"},{"key":"2955_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373.","journal-title":"Lancet Oncol"},{"key":"2955_CR23","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"2955_CR24","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391.","journal-title":"N Engl J Med"},{"key":"2955_CR25","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol. 2012;30:2946\u201355.","journal-title":"J Clin Oncol"},{"key":"2955_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"A Badros","year":"2025","unstructured":"Badros A, Foster L, Anderson LD Jr., Chaulagain CP, Pettijohn E, Cowan AJ, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145:300\u201310.","journal-title":"Blood"},{"key":"2955_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"2955_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J Clin Oncol. 2025;43:1279\u201388.","journal-title":"J Clin Oncol"},{"key":"2955_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"E Zamagni","year":"2024","unstructured":"Zamagni E, Silzle T, \u0160pi\u010dka I, Tahri S, Lonergan S, Nijhof IS, et al. Phase 3 study of teclistamab (tec) in combination with lenalidomide (len) and tec alone versus len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the MajesTEC-4\/EMN30 trial. Blood. 2024;144:494.","journal-title":"Blood"},{"key":"2955_CR30","doi-asserted-by":"crossref","unstructured":"Mateos MV, Grosicki S, Kim K, Negre E, Vandendries E. MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. Am Soc Clin Oncol. 2023;41:TPS8066-TPS8066.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"key":"2955_CR31","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. J Clin Oncol. 2023;41:3945\u201355.","journal-title":"J Clin Oncol"},{"key":"2955_CR32","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosinol","year":"2023","unstructured":"Rosinol L, Oriol A, Rios R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142:1518\u201328.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02955-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:20Z","timestamp":1789119440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02955-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02955-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.T.B. reports a continuing education presentation for Postgraduate Healthcare Education, LLC supported by grant from Bristol Myers Squibb; advisory board for AstraZeneca; advisory board for Genmab. Q.V.W. reports consulting for Century Therapeutics. J.C. reports employment as Medical Science Liaison with Servier Pharmaceuticals. R.B. reports serving as a consultant for AbbVie, Adaptive Biotech, Bristol Myers Squibb (BMS), Caribou Biosciences, Genentech, Gilead\/Kite, GlaxoSmithKline, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, and SparkCures; and research funding from AbbVie, BMS, Janssen, Novartis, Pack Health, Prothena, and Sanofi. K.C. reports completion of advisory boards for Prothena, Johnson and Johnson; research funding from BMS. L.H. reports research funding from Sanofi, Millennium-Takeda, Bristol Myers Squibb, Merck Iteos, Immune Tolerance Network; royalty from Up-To-Date. A.K.G. reports research funding from Merck, I-Mab bio, IgM Bio, Takeda, Gilead, Astra-Zeneca, Agios, Janssen, BMS, SeaGen, Teva, Genmab, Beigene, Pfizer, Umoja; consultancy\/honoraria from Incyte, Kite, Morphosys\/Incyte, ADCT, Acrotech, Merck, Karyopharm, Servier, Beigene, Cellectar, Janssen, Compliment, SeaGen, Epizyme, I-Mab bio, Gilead, Genentech, Lilly, Caribou, Fresenius-Kabi, SciTech, Sana, Compliment; and stock options from Compliment Corporation, SciTech. A.J.C. reports consulting or advisory role with HopeAI, Sebia, Janssen, Bristol Myers Squibb\/Celgene\/Juno, Sanofi, Adaptive Biotechnologies, AbbVie; research funding from Janssen (Inst), Bristol Myers Squibb\/Celgene\/Juno (Inst), Sanofi (Inst), Regeneron (Inst), Nektar (Inst), IgM Biosciences (Inst), Karyopharm Therapeutics (Inst), Harpoon Therapeutics (Inst), Opna Bio (Inst). A.P. reports consulting for Capvision and Karyopharm. The remaining authors have no disclosures to report.","order":1,"name":"Ethics","label":"Conflict of interest disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This is an IRB-approved study that is compliant with ethical practices in clinical studies and was considered minimal risk\/exempt by the institution IRB due to retrospective chart reviews. The study was approved by the Fred Hutchinson Cancer Center Institutional Review Board and conducted under a waiver of informed consent.","order":2,"name":"Ethics","label":"Ethics approval statement & patient consent statement","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}